• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Angeles Equity Partners Appoints Debbie White to Xanitos Board of Directors

    7/14/21 7:00:00 AM ET
    $PAVM
    Medical/Dental Instruments
    Health Care
    Get the next $PAVM alert in real time by email

    Global Industry Executive Plans to Leverage On-Site Healthcare Services Experience to Help Drive Growth and Continued Excellence in Service Delivery

    Angeles Equity Partners, LLC ("Angeles"), a private investment firm focused on value creation through operational transformation, today announced the appointment of Debbie White to the Board of Directors of Xanitos. Naming Ms. White to the Board adds an experienced industry executive to help steer Xanitos' strategic plan to become the premier specialty provider of environmental services (EVS), patient transport, and linen services to hospitals and other acute care settings nationwide.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210714005328/en/

    Debbie White (Photo: Business Wire)

    Debbie White (Photo: Business Wire)

    "Ms. White's broad business leadership experience as a chief executive, financial executive, public company director, and strategic consultant, combined with her deep on-site services background in Europe and the United States, make her an ideal partner for Xanitos and Angeles as we target the next phase of growth for the company," said Timothy Meyer and Jordan Katz, Co-Founders and Managing Partners of Angeles Equity Partners. "We are thrilled to have Debbie join the Board and look forward to her playing an important role with Xanitos going forward."

    Ms. White brings to Xanitos more than 35 years of experience in strategy, operations, and finance, primarily in on-site services businesses. Ms. White previously served as Group CEO of Interserve Group (LSE: IRV). Before Interserve, Ms. White spent 13 years in senior executive roles at Sodexo SA (Euronext: SW), where she served as the global CEO of both the Healthcare and Government business units. At Interserve and Sodexo, she improved operational performance and drove growth through a focus on simplification and standardization, employee engagement, and a deep understanding of clients' changing expectations. Ms. White also served on Sodexo's global team that promoted the development of women across the company and was inducted into the industry's Women 1st Top 100 Club, which highlights the female role models and leaders who have achieved success at the highest levels.

    Early in the COVID-19 pandemic, Ms. White worked with the UK government to help establish COVID-19 testing facilities across the nation. She currently serves on the Board of Directors for PAVmed (NASDAQ:PAVM, PAVMZ))) and Howden Joinery Group PLC (LSE: HWDN). She is a trustee of Wellbeing of Women, a UK charity that invests in medical research and development of specialist clinicians in women's health. Ms. White recently served as a strategic consultant to Oxford Nanopore Technologies Ltd., a UK biotechnology company that develops and commercializes DNA/RNA sequencing technologies.

    Ms. White previously served as a Director at PWC Consulting, advising a range of industries, including pharmaceuticals, on integration, financial performance improvement, and post-merger integration. She served for 13 years in various financial and strategic roles at AstraZeneca (LSE: AZN). Ms. White began her career as a senior tax advisor at Arthur Andersen & Co. after receiving her master's degree in Economics from Cambridge University.

    "I am excited to work with the Xanitos team to scale the business to achieve a national leadership position in the sector. Dave Crothall and his team have built a company recognized for its high quality of service and dedication to providing excellent patient care support services. Their mission-driven culture and dedication to client satisfaction set them apart," said Debbie White, Director of Xanitos. "I look forward to helping Xanitos grow and expand on their mission to improve patient care, helping save lives."

    "We are excited to welcome Ms. White to the Xanitos board," said Dave Crothall, CEO of Xanitos. "We believe her depth of experience as a proven leader in our sector will be immensely valuable as we scale our business."

    About Angeles Equity Partners, LLC

    Angeles Equity Partners, LLC is a private equity firm that invests in companies across a wide range of sectors and specifically targets businesses which it believes can directly benefit from the firm's strategic, operational, and M&A capabilities. The Angeles skill set drives the firm's investment philosophy and, in its view, can help businesses reach their full potential. Learn more online at www.angelesequity.com.

    About Xanitos

    Founded in 2008 by Graeme Crothall, Xanitos provides hospital housekeeping, patient transport, and linen services to hospitals and other acute care settings nationwide. Xanitos is differentiated by its XRO® System in which dirt, dust, and pathogens are removed from the hospital, creating a cleaner and safer environment. As a quality- and service-oriented company, Xanitos continues to apply the same principles of retaining and growing its team to retaining and growing its hospital partnerships. Xanitos' passion is helping to save lives and partnering with client hospitals to deliver the best possible environment of care for patients. Learn more online at www.xanitos.com.

    This is not an offer or solicitation to sell securities.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20210714005328/en/

    Get the next $PAVM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PAVM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PAVM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on PAVmed with a new price target

    Cantor Fitzgerald initiated coverage of PAVmed with a rating of Overweight and set a new price target of $8.00

    3/30/21 6:22:24 AM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    Lake Street Capital reiterated coverage on PAVmed with a new price target

    Lake Street Capital reiterated coverage of PAVmed with a rating of Buy and set a new price target of $9.00 from $5.00 previously

    2/22/21 4:33:18 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    $PAVM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PAVmed Closes Preferred Stock and Senior Secured Note Financings, Eliminating All Previously Outstanding Convertible Securities

    Series D Preferred Stock offering yielded $30 million of gross proceeds and includes warrants exercisable for up to an additional $30 million upon publication of a positive draft EsoGuard Medicare local coverage determination Series D Preferred Stock convertible into common stock subject to stockholder approval at an upcoming special meeting New senior secured note with three-year maturity yielded an additional $15 million of gross proceeds Proceeds used to redeem and retire all previously outstanding convertible securities, eliminating a significant legacy capital structure overhang Transactions yielded approximately $7.7 million in net cash proceeds, materially strengthening the Company's

    2/4/26 8:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    Lucid Diagnostics Awarded U.S. Department of Veterans Affairs Contract for EsoGuard®

    NEW YORK, Jan. 21, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it has been awarded a contract by the U.S. Department of Veterans Affairs (VA) for its EsoGuard® Esophageal DNA Test, expanding access to esophageal precancer testing across the nation's largest integrated healthcare system, which serves more than nine million enrolled veterans annually. The contract is issued under the VA Federal Supply Schedu

    1/21/26 8:00:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    PAVmed Announces Reverse Stock Split

    NEW YORK, Dec. 30, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced it will conduct a 1-for-30 reverse stock split of its common stock (the "Common Stock"). The reverse stock split will become effective on January 2, 2026, at 12:01 a.m. Eastern Time. The Company's Common Stock will continue to trade on the Nasdaq Capital Market ("Nasdaq") under the symbol "PAVM" and will begin trading on a split-adjusted basis at the opening of the market on January 2, 2026. The reverse stock split is intended to bring the Company into

    12/30/25 9:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    $PAVM
    SEC Filings

    View All

    SEC Form DEF 14A filed by PAVmed Inc.

    DEF 14A - PAVmed Inc. (0001624326) (Filer)

    2/24/26 4:15:16 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    SEC Form D filed by PAVmed Inc.

    D - PAVmed Inc. (0001624326) (Filer)

    2/17/26 8:39:16 AM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    SEC Form PRE 14A filed by PAVmed Inc.

    PRE 14A - PAVmed Inc. (0001624326) (Filer)

    2/13/26 5:00:23 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    $PAVM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Sparks Ronald M was granted 150,000 shares, increasing direct ownership by 231% to 215,000 units (SEC Form 4)

    4 - PAVmed Inc. (0001624326) (Issuer)

    10/2/25 4:22:08 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    Director White Debra was granted 150,000 shares, increasing direct ownership by 231% to 215,000 units (SEC Form 4)

    4 - PAVmed Inc. (0001624326) (Issuer)

    10/2/25 4:21:10 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    Director Baxter Timothy E was granted 150,000 shares, increasing direct ownership by 231% to 215,000 units (SEC Form 4)

    4 - PAVmed Inc. (0001624326) (Issuer)

    10/2/25 4:20:04 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    $PAVM
    Leadership Updates

    Live Leadership Updates

    View All

    Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors

    Growth-focused healthcare executive brings 40 years of executive leadership experience across multiple industry sectors NEW YORK, Sept. 25, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ: PAVM), today announced the appointment of accomplished healthcare executive John R. Palumbo to its Board of Directors, effective September 22, 2025. "John is a highly accomplished executive whose 40 years of healthcare leadership experience spans earl

    9/25/25 8:01:00 AM ET
    $LUCD
    $MDRX
    $PAVM
    Medical/Dental Instruments
    Health Care
    EDP Services
    Technology

    Lucid Diagnostics Appoints Danielle Scelfo as Senior Vice President, Market Access & Government Affairs

    Scelfo to strengthen and scale Lucid's market access infrastructure ahead of key upcoming reimbursement milestones—including Medicare coverage for EsoGuard—and to accelerate commercial coverage expansion NEW YORK, Sept. 16, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced the appointment of Danielle Scelfo as Senior Vice President, Market Access & Government Affairs, reporting to the Chief Executive Officer. Ms. Scelfo is widely recognized in the diagnostics industry as an accomplished health policy leader with more than 25 years o

    9/16/25 8:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes

    NEW YORK, May 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as part of their 2025 annual reconstitution, according to a preliminary list of additions posted by FTSE Russell on May 23, 2025. "We are pleased that Lucid is joining these importa

    5/27/25 7:31:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    $PAVM
    Financials

    Live finance-specific insights

    View All

    PAVmed to Hold a Business Update Conference Call and Webcast on November 13, 2025

    Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, Oct. 30, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Thursday, November 13, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update including an overview of the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the Company's thi

    10/30/25 8:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 12, 2025

    Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, Oct. 29, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it will host a business update conference call and webcast on Wednesday, November 12, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's third quarter 2025 f

    10/29/25 8:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    Lucid Diagnostics to Host Investor Call on Monday, September 8, 2025

    Conference call scheduled for Monday, September 8, at 8:30 AM ET to discuss September 4 MolDX Contractor Advisory Committee (CAC) meeting NEW YORK, Sept. 5, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM) ("PAVmed"), today announced it will host a conference call on Monday, September 8, 2025, at 8:30 a.m. Eastern Time to discuss the September 4 Contractor Advisory Committee ("CAC") Meeting convened by MolDX-participating Medicare Administrative Contractors as part of the reconsideration of Local Coverage Determination (LCD) L39256, "MolDX: Molec

    9/5/25 9:16:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    $PAVM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by PAVmed Inc.

    SC 13G - PAVmed Inc. (0001624326) (Subject)

    11/14/24 10:02:46 AM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by PAVmed Inc.

    SC 13G - PAVmed Inc. (0001624326) (Subject)

    9/23/24 8:46:15 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by PAVmed Inc.

    SC 13G - PAVmed Inc. (0001624326) (Subject)

    2/14/24 3:38:38 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care